Curia recognized for its Service in the CDMO industry
ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small Pharma group. In its 13th year, the awards are presented by Outsourced Pharma and Life Science Leader.
“Curia is honored to receive this award,” said Philip Macnabb, CEO, Curia. “This distinction underscores our commitment to creating value for our customers across all of our R&D and manufacturing offerings, and we are especially appreciative to be acknowledged by the partners we support for that commitment.”
Winners of CDMO Leadership Awards are selected based on market research by Industry Standard Research (“ISR”) to distinguish CDMOs that meet or exceed customer expectations. For the 2024 awards, 98 contract manufacturers were evaluated by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Respondents to the survey only evaluate companies with which they have worked on an outsourced project within the past 18 months. Curia was awarded based on the feedback of respondents in the Small Pharma category.
“Congratulations to our 2024 CDMO Leadership Award winners. By vote of your customers, you are recognized as the best in the global outsourcing development and manufacturing sector of the biopharma industry,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “Award winners maintained and expanded capabilities and expertise to meet the needs of a diverse customer base; provided the additional quality and reliability so crucial to novel processes and products; and forged the closest relationships with customers. 2023 rang in with many unsettled questions. The 2024 CDMO Leadership Award winners are the support companies that best answered the bell over the past year.”
About Curia
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with Biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecules offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.
Corporate Contact: |
Viana Bhagan |
Curia |
+1 518 512 2111 |
corporatecommunications@CuriaGlobal.com |
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/328a3a12-3a66-4a34-bdc8-e5de362efb85
GLOBENEWSWIRE (Distribution ID 9031149)
- 老杨第一次再度抓握住一瓶水,他由此产生了新的憧憬
- 丰田章男称未来依然需要内燃机 已经启动电动机新项目
- B站更新决策机构名单:共有 29 名掌权管理者,包括陈睿、徐逸、李旎、樊欣等人
- 苹果罕见大降价,华为的压力给到了?
- 三明列东又有房子要拆迁!住这里的人要发了!
- 放大招后,广州又忍不住了…
- 私募积极加仓,百亿股票私募仓位指数创出近八周新高
- 他,传闻中马云最想见的人
- 升级的脉脉,正在以招聘业务铺开商业化版图
- 如何经营一家好企业,需要具备什么要素特点
- 智慧驱动 共创未来| 东芝硬盘创新数据存储技术
- 创意驱动增长,Adobe护城河够深吗?
- 全力打造中国“创业之都”名片,第十届中国创业者大会将在郑州召开
- 疫情期间 这个品牌实现了疯狂扩张